Comparison outcomes of a large cohort of moderate and severe COVID-19 patients received different Antiviral and Anti Inflammatory Drugs.
Aim of the study 1. To assess the difference in patients' clinical status improvement between patients. 2. To detect time to improvement in oxygenation among both groups. 3. To detect duration of hospitalization and mortality rate in both groups. 4. To detect incidence and duration of mechanical ventilation in both treatment arms. 5. To monitor of adverse events of both drugs
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
150
Remdesivir will be administrated intravenously (IV) at a dose of 200 mg at day 1 then 100 mg once daily for 5 days.
Hydroxychloroquine will be administrated at a dose of 400 mg twice daily at day 1 then 200 mg twice daily for 5 days.
Tocilizumab 800 mg once.
Beni-suef University
Banī Suwayf, Egypt
RECRUITINGPercentage of clinical cure in each arm
Proportion of cured patients in the interventional group versus the proportion of cured patients in the control group before and after starting drugs
Time frame: through an average of 5-7 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Lopinavir / ritonavir at a dose of 400 /100 once daily for 5 days.
Ivermectin 36 mg at day 1,3 and 6.